| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SGEN | Common Stock | Award | $0 | +13.1K | +17.33% | $0.00 | 88.7K | Aug 15, 2023 | Direct | F1, F2, F3 |
| transaction | SGEN | Common Stock | Disposed to Issuer | -$139K | -717 | -0.81% | $193.87 | 88K | Aug 16, 2023 | Direct | F3, F4 |
| transaction | SGEN | Common Stock | Disposed to Issuer | -$179K | -922 | -1.05% | $193.87 | 87.1K | Aug 16, 2023 | Direct | F3, F5 |
| transaction | SGEN | Common Stock | Disposed to Issuer | -$265K | -1.37K | -1.57% | $193.87 | 85.7K | Aug 16, 2023 | Direct | F3, F6 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | These shares represent restricted stock units and will be settled in common stock upon vesting. 40% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer closes. |
| F2 | Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years. |
| F3 | Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting. |
| F4 | The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/3/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). |
| F5 | The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/1/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). |
| F6 | The sales reported in this Form 4 were effected pursuant to a written plan adopted on 9/7/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). |